Autocrine costimulation: Tumor-specific CD28-mediated costimulation of T cells by in situ production of a bifunctional B7-anti-CEA diabody fusion protein

Cancer Gene Therapy

Volumn 9, Issue 3, 2002, Pages 275-281

  Blanco, Belén ^a   Holliger, Philipp ^b   Álvarez Vallina, Luis ^a  

^a HOSPITAL UNIVERSITARIO PUERTA DE HIERRO   (Spain)

^b MRC LABORATORY OF MOLECULAR BIOLOGY   (United Kingdom)

Author keywords

Cancer; Gene therapy; Immunotherapy; Tumor specific costimulation

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; CD28 ANTIGEN; HYBRID PROTEIN; T LYMPHOCYTE RECEPTOR;

ANTIGEN RECOGNITION; ANTINEOPLASTIC ACTIVITY; ARTICLE; AUTOCRINE EFFECT; CANCER SURVIVAL; CELL INFILTRATION; CELL PROLIFERATION; CLONAL ANERGY; CONTROLLED STUDY; DNA MODIFICATION; FLOW CYTOMETRY; GENE THERAPY; HUMAN; HUMAN CELL; IMMUNOTHERAPY; PARACRINE SIGNALING; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; T LYMPHOCYTE ACTIVATION;

ANTIGENS, CD28; ANTIGENS, CD80; AUTOCRINE COMMUNICATION; CARCINOEMBRYONIC ANTIGEN; COLONIC NEOPLASMS; CYTOTOXICITY, IMMUNOLOGIC; DNA PRIMERS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; GENE THERAPY; HUMANS; IMMUNOTHERAPY; INTERLEUKIN-2; LYMPHOCYTE ACTIVATION; LYMPHOCYTES, TUMOR-INFILTRATING; RECOMBINANT FUSION PROTEINS; T-LYMPHOCYTES; TUMOR CELLS, CULTURED;

EID: 85047697591     PISSN: 09291903     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.cgt.7700438     Document Type: Article

References (25)

1. Antigen recognition by class I-restricted T lymphocytes
2. The ups and downs of T cell costimulation
3. Induction of alloantigen-specific hyporesponsiveness in human T lymphocytes by blocking interaction of CD28 with its natural ligand B7/BB1
4. Clonal expansion versus functional clonal inactivation: A costimulatory signalling pathway determines the outcome of T cell antigen receptor occupancy
5. The role of the CD28 receptor during T cell responses to antigen
6. CD28-B7 interactions in T-cell activation
7. Manipulation of T cell responses to tumors by targeting on costimulatory pathway
8. Costimulation of antitumor immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4
9. Tumor immunogenicity determines the effect of B7 costimulation on T cell-mediated tumor immunity
10. Antigen-specific targeting of CD28-mediated T cell co-stimulation using chimeric single-chain antibody variable fragment-CD28 receptors
11. Targeted cell immunotherapy of human cancer: A promising approach that is extending its initial cell and molecular scope
12. Antigen-dependent CD28 signaling selectively enhances survival and proliferation in genetically modified activated human primary T lymphocytes
13. Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors
14. Chimeric receptors providing both primary and costimulatory signaling in T cells from a single gene product
15. Genetic approaches for antigen-selective therapy
16. Costimulation of T cell proliferation by a chimeric B7-2 antibody fusion protein specifically targeted to cells expressing the erbB2 proto-oncogene
17. Construction and characterization of bispecific costimulatory molecules containing a minimized CD86 (B7-2) domain and single-chain antibody fragments for tumor targeting
18. Carcinoembryonic antigen (CEA)-specific T-cell activation in colon carcinoma induced by anti-CD3xanti-CEA bispecific diabodies and B7xanti-CEA bispecific fusion proteins
19. Engineering and characterization of a novel fusion protein incorporating B7.2 and an anti-ErbB-2 single-chain antibody fragment for the activation of Jurkat T cells
20. A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes
21. T cell targeting in cancer therapy
22. Diabodies: Small bivalent and bispecific antibody fragments
23. Genetic approach to facilitate purification of recombinant proteins with a novel metal cHeLate adsorbent
24. Pharmacological control of antigen responsiveness in genetically modified T lymphocytes
25. Delimitation of the proliferative stages in the human thymus indicates that cell expansion occurs before the expression of CD3 (T cell receptor)